Struggling ‘digital therapeutics’ startup Pear Therapeutics explores sale


The startup behind the first-ever prescription software to be approved by the U.S. Food and Drug Administration is looking to sell itself.

Previous Pittsburgh banks lost $12.9 billion in value amid industry's turmoil
Next Why serial entrepreneur Robbie Allen's next venture is in health care